Brokerages Set Pluristem Therapeutics Inc. (NASDAQ:PSTI) PT at $14.50

Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) have been assigned an average rating of “Buy” from the six analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.50.

A number of equities research analysts have recently weighed in on the company. Dawson James reaffirmed a “buy” rating on shares of Pluristem Therapeutics in a research note on Wednesday, April 15th. ValuEngine downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Maxim Group restated a “buy” rating and set a $12.00 price target on shares of Pluristem Therapeutics in a research note on Friday, May 15th. Jefferies Financial Group increased their target price on shares of Pluristem Therapeutics from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.50 price target on shares of Pluristem Therapeutics in a research report on Thursday, May 14th.

NASDAQ PSTI opened at $9.80 on Tuesday. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.06. Pluristem Therapeutics has a 1-year low of $2.82 and a 1-year high of $13.29. The firm’s fifty day simple moving average is $8.46 and its 200-day simple moving average is $6.51.

In other Pluristem Therapeutics news, major shareholder Clover Wolf Capital – Limited bought 121,926 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of $9.03 per share, for a total transaction of $1,100,991.78. Following the purchase, the insider now directly owns 3,663,966 shares in the company, valued at $33,085,612.98. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have acquired 835,832 shares of company stock valued at $6,625,928. Company insiders own 4.90% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in shares of Pluristem Therapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock valued at $1,077,000 after buying an additional 87,188 shares during the last quarter. Jane Street Group LLC raised its holdings in Pluristem Therapeutics by 303.9% in the 4th quarter. Jane Street Group LLC now owns 67,349 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 50,674 shares in the last quarter. Levin Capital Strategies L.P. bought a new stake in shares of Pluristem Therapeutics in the 1st quarter worth approximately $37,000. Focused Wealth Management Inc acquired a new stake in shares of Pluristem Therapeutics during the 2nd quarter worth approximately $53,000. Finally, ETF Managers Group LLC increased its position in shares of Pluristem Therapeutics by 9.8% during the first quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 5,764 shares during the period. 7.82% of the stock is owned by hedge funds and other institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: CD Ladder

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.